Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Alemtuzumab is a man-made antibody used to treat certain blood disorders. Tacrolimus is a
drug used to decrease immune system activity in people who have received organ transplants so
that the new organ will not be rejected. This study will determine whether treatment with
alemtuzumab and tacrolimus is effective in preventing organ rejection and maintaining the
recipient's health after liver transplantation in patients with end-stage liver disease, and
whether gradual tapering of tacrolimus treatment is safe for these patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)